PRESENTATION

Q3 2025 — Presentation

Q3 2025PDF · 15 pages259 KB
Elevance Health
3Q 2025 Earnings Presentation
October 21, 2025

-- 1 of 15 --

2
Key Highlights
Elevance Health third quarter operational results consistent with expectations
• 	Benefit expense ratio of 91.3% in line with revised outlook
• 	Adjusted diluted EPS1 of $6.03 reflects ~$1 of higher net investment income and timing of certain tax benefits
• 	Reaffirm full year adjusted diluted EPS1 guidance of ~$30, including a benefit expense ratio of ~90.0% and
~$3 of discrete, non-core items
3Q 2025 Results &
2025 Outlook1
Providing insight into key planning assumptions; earnings guidance to be set in January:
• 	Disciplined positioning across Medicare Advantage, Commercial, and Individual ACA businesses
• 	Medicaid operating margin expected to decline by at least 125 basis points year-over-year, as rate increases lag
acuity and utilization trends
• 	Medicare Advantage membership impacted by approximately 150k members from service area and plan exits;
2026 bids prioritize pricing discipline and sustainable margin profile
• 	Carelon expected to deliver continued strong growth across both Pharmacy and Health Services; results will be
impacted by Health Benefits membership trends, with the full impact assessed in January
• 	Several hundred million dollars of incremental investments to scale Carelon, advance our AI and digital strategy,
and improve Star ratings
• 	2026 investments and Carelon expansion position Elevance Health for balanced earnings growth in 2027
2026 Considerations
2
• 	Scaling our enterprise flywheel through Carelon’s differentiated value-based care solutions
• 	Demonstrating steady improvement in Star ratings performance, with ~55% of Medicare Advantage members in
4-Star or higher contracts for payment year 2027, up from ~40%; three contracts achieved a 5-Star rating
• 	Expanding digital innovation such as HealthOS, AI-enabled clinical support, and our digital virtual assistant to
increase access to care, reduce costs, and create greater efficiency
• 	Deploying capital opportunistically, with a near-term focus on share repurchases
Strategic Focus
Areas3
1. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 2 of 15 --

33
Key Highlights
• 	Elevance Health third quarter results
reflect solid execution as we focus on the
levers within our control to deliver
sustainable, long-term performance
• 	Operating revenue of $50.1B grew 12.0%,
due to higher premium yields in Health
Benefits, recently closed acquisitions, and
Medicare Advantage membership growth,
partly offset by Medicaid reverifications
• 	Benefit expense ratio of 91.3% consistent
with expectations and reflecting elevated
cost trend across lines of business
• 	Adjusted operating expense ratio of 10.4%
includes targeted strategic investments
while maintaining cost discipline
• 	Operating cash flow of $1.1B impacted by
BCBSA Provider Settlement Agreement
payment
3Q 2025 Results
Change (%/bps)	3Q 2024	3Q 2025	Elevance Health
12.0%	$44.7B	$50.1B	Operating Revenue 1
180 bps	89.5%	91.3%	Benefit Expense Ratio
100 bps	9.4%	10.4%	Adjusted Operating Expense Ratio1,2
(45.3%)	$2.5B	$1.3B	Adjusted Operating Gain1,2
(280) bps	5.5%	2.7%	Adjusted Operating Margin 1,2
13.4%	$551M	$625M	Net Investment Income
(29.9%)	$8.60	$6.03	Adjusted Diluted EPS 2
($1.5B)	$2.7B	$1.1B	Operating Cash Flow
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 3 of 15 --

44
Key Highlights
• 	Health Benefits results were consistent
with expectations; reflect incremental
investments to support our long-term
performance
• 	Operating revenue grew 10.4% year over
year, driven by higher premium yields,
recently closed acquisitions, and growth
in Medicare Advantage membership,
partly offset by Medicaid reverifications
• 	Adjusted operating margin of 1.4%
declined by 280 bps due to elevated, but
anticipated, medical cost trends and
incremental investments to support our
workforce and accelerate technology
adoption
• 	Membership of 45.4M reflects lower
BlueCard membership and ongoing
Medicaid reverifications, offset by
targeted growth and higher retention
rates in Medicare Advantage
Change (%/bps)	3Q 2024	3Q 2025	Health Benefits
10.4%	$38.3B	$42.2B	Operating Revenue 1
(63.0%)	$1.6B	$0.6B	Adjusted Operating Gain1,2
(280) bps	4.2%	1.4%	Adjusted Operating Margin 1,2
(0.9%)	45.8M	45.4M	Membership
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “Reportable Segment Highlight Details” on slide 14 herein.
Health Benefits
3Q 2025 Results

-- 4 of 15 --

55
Key Highlights
• 	Carelon’s results driven by strength of
our integrated platform and continued
execution across Pharmacy and Services,
with investments to sustain growth
• 	CarelonRx operating revenue grew ~20%
driven by momentum with large clients
and recent specialty pharmacy
acquisitions; operating margin reflects
planned integration and technology
investments to support growth
• 	Carelon Services revenue up ~60%
supported by CareBridge integration and
expansion of risk-based and home-
health capabilities; operating margin
reflects expected seasonality and
continued scaling of the platform
3Q 2025 Results
Change (%/bps)	3Q 2024	3Q 2025	Carelon
32.9%	$13.8B	$18.3B	Operating Revenue 1
(9.5%)	$0.9B	$0.8B	Adjusted Operating Gain1,2
(200) bps	6.2%	4.2%	Adjusted Operating Margin 1,2
6.0%	80.2M	85.0M	Adjusted Scripts
(3.7%)	101.3M	97.6M	Consumers Served
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	See “Reportable Segment Highlight Details” on slide 14 herein.
Health Services

-- 5 of 15 --

66
Elevance Health is a Lifetime, Trusted Health Partner
Lowering the cost of healthcare
We anticipate health trends early, give
caregivers the tools they need, and
make care easier to afford.
Making healthcare simple
We make accessing and using healthcare easy,
cutting red tape and simplifying systems and
processes so providers can provide care, and
members can live their healthiest lives.
To deliver on our mission of improving lives and communities and simplifying healthcare
WHAT
HOW
WHY
A lifetime, trusted health partner
committed to making healthcare
better…better costs, better experience,
better outcomes – for your whole health.

-- 6 of 15 --

77
Flywheel Supports Our Long-Term Growth Algorithm
Health Benefits
Optimize
the Core
Invest in
Growth
Accelerate
Targeting at least 12% average annual growth in
Adjusted Diluted Earnings Per Share
Over 45M medical members balanced
across commercial, Medicaid, Medicare,
and the Federal Employee Program,
leveraging the assets and capabilities
of Carelon to accelerate growth
As an integrated portfolio of whole
health solutions serving approximately
100M consumers, Carelon connects care
across physical, behavioral, social,
home health, and pharmacy needs to
bend the cost curve, enhance consumer
experiences, and deliver whole health,
affordably
Health Services

-- 7 of 15 --

88
Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR1
Long-Term Growth Algorithm
Revenue Growth
High Single Digit CAGR1
Adjusted Operating Margin
Expanding to 6.5% - 7.0%
Capital Deployment
Approximately 4% Contribution to
Adjusted Diluted EPS CAGR 1
Health Benefits
Mid to High Single Digit CAGR
Driven by membership growth, cost trend, geographic
expansion, and growth in specialized populations
Carelon Services
High Teens to Low Twenties CAGR
Driven by risk-based revenue growth including M&A
CarelonRx
Low Double Digit CAGR
Driven by script volumes and drug mix
Transforming our business
processes by leveraging new
technologies across operations
Commitment to operating
efficiency and optimizing core
businesses
Effective medical management
Underwriting discipline
Share Repurchases
Organic Reinvestment
Programmatic M&A targeting
integrated solutions that
strengthen health plan
competitiveness
+ 	+
Targeting at least 12% average annual growth in Adjusted Diluted EPS
1. 	CAGR = Compound Annual Growth Rate Target.

-- 8 of 15 --

99
Committed to Strong Growth Over the Long-Term
M&A/ Organic
Reinvestment
50%
Share
Repurchase
30%
Dividends
20%
5.3%
6.5% – 7.0%
2024 	Target
$175B
High Single
Digit CAGR1
2024 	Target
Elevance Health
5.8%
Mid to High
Single Digit
2024 	Target
$54B
Mid Teens
CAGR1
2024 	Target
Carelon 2
4.2%
5.5% – 6.5%
2024 	Target
$150B
Mid to High
Single Digit
CAGR1
2024 	Target
Health Benefits
Capital
Allocation
Targeting at least 12% average annual
growth in Adjusted Diluted EPS
Adjusted 3
Operating
Margin
Revenue
(in billions)
1. 	CAGR = Compound Annual Growth Rate Target.
2. 	The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx,
and (ii) a high teens to low twenties revenue CAGR and mid to high single digit operating margin for Carelon Services.
3. 	See “GAAP Reconciliation” on slides 12 and 13 herein.

-- 9 of 15 --

10
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views
about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,”
“project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and
estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements
regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could
cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our
reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the
extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties
include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large
scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws
or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application;
the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations,
claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial
intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that
may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic
growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed
thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to
revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits
or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and
services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS
Health, L.L.C.; the effects of any negative publicity related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and
strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in
the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our
common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness
and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings;
events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our
international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

-- 10 of 15 --

11
Non-GAAP Measures and Basis of Presentation
This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and
are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures
calculated in accordance with GAAP are available on Slides 12-13 of this document.
Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set
incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of
products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible
assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in
understanding and analyzing Elevance Health’s operating and financial results.

-- 11 of 15 --

12	12
Elevance Health GAAP Reconciliation — Shareholders’ Net Income
and Shareholders’ Earnings Per Diluted Share Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2024	2025	Change	2024	2025	(In millions, except per share data)
(8.0)%	$5,562	$5,115	17.0%	$1,016	$1,189	Shareholders' net income
Add / (Subtract):
400	464	122	162	Amortization of other intangible assets
158	182	42	49	Transaction and integration related costs1
680	19	669	4	Litigation and settlement expenses1
371	596	125	1	Net losses on financial instruments
191	—	72	—	Business dispositions and related items 2
(201)	—	39	—	(Gain) loss on sale of business
268	(4)	268	(4)	Business optimization charges 1
(482)	(307)	(348)	(52)	Tax impact of non-GAAP adjustments
1,385	950	989	160	Net adjustment items
(12.7)%	$6,947	$6,065	(32.7)%	$2,005	$1,349	Adjusted shareholders' net income
(4.8)%	$23.81	$22.67	22.0%	$4.36	$5.32	Shareholders’ earnings per diluted share
Add / (Subtract):
1.71	2.06	0.52	0.72	Amortization of other intangible assets
0.68	0.81	0.18	0.22	Transaction and integration related costs1
2.91	0.08	2.87	0.02	Litigation and settlement expenses1
1.59	2.64	0.54	—	Net losses on financial instruments
0.82	—	0.31	—	Business dispositions and related items 2
(0.86)	—	0.17	—	(Gain) loss on sale of business
1.15	(0.02)	1.15	(0.02)	Business optimization charges 1
(2.06)	(1.36)	(1.49)	(0.23)	Tax impact of non-GAAP adjustments
5.93	4.21	4.24	0.71	Net adjustment items
(9.6)%	$29.74	$26.88	(29.9)%	$8.60	$6.03	Adjusted shareholders’ earnings per diluted share
Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2024	2025	Change	2024	2025	(In millions)
(11.0)%	$7,298	$6,495	2.4%	$1,373	$1,406	Income before income tax expense
(1,524)	(1,701)	(551)	(625)	Net investment income
(201)	—	39	—	(Gain) loss on sale of business
371	596	125	1	Net losses on financial instruments
845	1,036	300	351	Interest expense
400	464	122	162	Amortization of other intangible assets
(4.2)%	$7,189	$6,890	(8.0)%	$1,408	$1,295	Reportable segments operating gain
1. 	Adjustment item resides in the Corporate & Other reportable segment.
2. 	Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
3. 	Totals may not foot due to rounding.

-- 12 of 15 --

13	13
Elevance Health GAAP Reconciliation — Operating Gain, Operating
Expense Ratio, and 2025 Outlook
Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2024	2025	Change	2024	2025	(In millions)
2.3%	$15,221	$15,569	0.1%	$5,269	$5,272	Operating expense
Add / (Subtract):
(158)	(182)	(42)	(49)	Transaction and integration related costs1
(680)	(19)	(669)	(4)	Litigation and settlement expenses1
(191)	—	(72)	—	Business dispositions and related items 2
(268)	4	(268)	4	Business optimization charges 1
(1,297)	(197)	(1,051)	(49)	Net adjustment items
10.4%	$13,924	$15,372	23.8%	$4,218	$5,223	Adjusted operating expense
13.9%	$130,215	$148,273	12.0%	$44,719	$50,087	Operating revenue
(120) bp	11.7%	10.5%	(130) bp	11.8%	10.5%	Operating expense ratio
(30) bp	10.7%	10.4%	100 bp	9.4%	10.4%	Adjusted operating expense ratio
Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2024	2025	Change	2024	2025	(In millions)
(4.2)%	$7,189	$6,890	(8.0)%	$1,408	$1,295	Reportable segments operating gain
Add / (Subtract):
158	182	42	49	Transaction and integration related costs1
680	19	669	4	Litigation and settlement expenses1
191	—	72	—	Business dispositions and related items 2
268	(4)	268	(4)	Business optimization charges 1
1,297	197	1,051	49	Net adjustment Items
(16.5)%	$8,486	$7,087	(45.3)%	$2,459	$1,344	Reportable segments adjusted operating gain
Full Year 2025
Outlook
Approximately $24.70	Shareholders’ earnings per diluted share
Add / (Subtract):
$2.98	Amortization of other intangible assets3
$2.90	Net losses on financial instruments3
$1.03	Transaction and integration related costs1, 3
$0.10	Litigation and settlement expenses1, 3
($0.02)	Business optimization charges 1
Approximately ($1.69)	Tax impact of non-GAAP adjustments3
$5.30	Net adjustment items
Approximately $30.00	Adjusted shareholders’ earnings per diluted share
1. 	Adjustment item resides in the Corporate & Other reportable segment.
2. 	Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
3. 	Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.

-- 13 of 15 --

14	14
Elevance Health
Reportable Segment & Health Benefits Revenue Details
Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2024	2025	Change	2024	2025	(In millions, Unaudited)
Operating Revenue
11.1%	$112,695	$125,259	10.4%	$38,278	$42,246	Health Benefits
22.2%	25,984	31,756	20.3%	9,143	10,997	CarelonRx
61.5%	13,192	21,301	57.9%	4,638	7,324	Carelon Services
69.0%	323	546	101.4%	74	149	Corporate & Other
NM 6	(21,979)	(30,589)	NM 6	(7,414)	(10,629)	Eliminations
13.9%	$130,215	$148,273	12.0%	$44,719	$50,087	Total Operating Revenue1
Operating Gain (Loss)
(27.5)%	$6,036	$4,378	(62.5)%	$1,604	$601	Health Benefits 2
3.4%	1,639	1,694	(10.2)%	619	556	CarelonRx
62.8%	682	1,110	19.0%	184	219	Carelon Services2
NM 6	(1,168)	(292)	NM 6	(999)	(81)	Corporate & Other 2,3
(4.2)%	$7,189	$6,890	(8.0)%	$1,408	$1,295	Total Operating Gain1,4
Operating Margin
(190) bp	5.4%	3.5%	(280) bp	4.2%	1.4%	Health Benefits
(100) bp	6.3%	5.3%	(170) bp	6.8%	5.1%	CarelonRx
— bp	5.2%	5.2%	(100) bp	4.0%	3.0%	Carelon Services
(90) bp	5.5%	4.6%	(50) bp	3.1%	2.6%	Total Operating Margin1
1. 	See “Basis of Presentation” on slide 11 herein.
2. 	Operating Gain for the three and nine months ended September 30, 2024, included $72 and $191 million, respectively, of 2024 business dispositions and related items; including $53 and $141 million, respectively, for the Carelon Services segment; and $19 and $50 million, respectively, for the Health
Benefits segment. Operating Gain for the three and nine months ended September 30, 2024, included $42 and $158 million, respectively, of transaction and integration related costs, $669 and $680 million, respectively, of litigation and settlement expenses, and $268 and $268 million, respectively, of
business optimization charges, all of which reside in the Corporate & Other reportable segment.
3. 	Operating Gain for the three and nine months ended September 30, 2025, included $49 and $182 million, respectively, of transaction and integration related costs, $4 and $19 million, respectively, of litigation and settlement expenses, and ($4) and ($4), respectively, of business optimization charges,
all of which reside in the Corporate & Other reportable segment.
4. 	Operating Gain for the three and nine months ended September 30, 2025, and September 30, 2024, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on slides 12 and 13 herein.
5. 	The Individual business, including ACA products, is reported as part of Commercial Operating Revenue.
6. 	"NM" = calculation not meaningful.
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program
businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not
allocated to our other reportable segments).
Nine Months Ended Sep 30	Three Months Ended Sep 30
Change	2024	2025	Change	2024	2025	(In millions, Unaudited)
Health Benefits Operating Revenue
7.7%	$34,965	$37,654	10.4%	$11,639	$12,849	Commercial
14.1%	6,178	7,047	13.3%	2,082	2,358	Individual 5
22.5%	27,741	33,990	18.7%	9,385	11,138	Medicare
7.5%	39,182	42,120	8.4%	13,063	14,166	Medicaid
6.4%	10,807	11,495	(2.3)%	4,191	4,093	Federal Employee Program
11.1%	$112,695	$125,259	10.4%	$38,278	$42,246	Total Health Benefits Operating Revenue1

-- 14 of 15 --



-- 15 of 15 --